Meghan Fitzgerald
CIK 1349297 · EVP, Strategy & Health Policy · last filed 2026-07-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$10.16M
Companies
6
Total Filings
36
Lifetime Open-Market Net
-$5.95M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ROIV | Director | 42,963 | $37.37 | $1.61M | -$2.27M | 9 | 2026-07-02 |
| THC | Director | 17,087 | $270.21 | $4.62M | -$3.68M | 15 | 2026-05-28 |
| Roivant Sciences Ltd. (ROIVW) Delisted | Director | 1,152 | $2.75 | $3.2K | $0 | 2 | 2023-07-06 |
| CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | Director | — | $8.37 | — | $0 | 3 | 2018-06-18 |
| CAH | EVP, Strategy & Health Policy | 16,760 | $234.98 | $3.94M | $0 | 3 | 2015-11-17 |
| VION PHARMACEUTICALS INC (VION) Delisted | VP and Chief Business Officer | 55,500 | — | — | $0 | 1 | 2007-03-14 |
Recent Filings · Page 2 of 4
36 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-08-08 | THC | Sell (S) | −20,000 | -$2.93M | EDGAR |
| 2024-08-06 | THC | Notice (144) | −20,000 | -$2.93M | EDGAR |
| 2024-05-28 | THC | Grant (A) | — | $0 | EDGAR |
| 2024-04-26 | ROIV | Mixed | +1,178 | -$905 | EDGAR |
| 2024-01-23 | ROIV | Grant (A) | +1,328 | $0 | EDGAR |
| 2023-10-18 | ROIV | Grant (A) | +1,269 | $0 | EDGAR |
| 2023-09-14 | ROIV | Grant (A) | +8,937 | $0 | EDGAR |
| 2023-07-06 | Roivant Sciences Ltd. (ROIVW) Delisted | Grant (A) | +1,152 | $0 | EDGAR |
| 2023-06-23 | THC | Grant (A) | +3,682 | $0 | EDGAR |
| 2023-05-30 | THC | Grant (A) | +2,846 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.